Last reviewed · How we verify

Supplementation of iron sucrose

Medical University of Vienna · FDA-approved active Small molecule

Supplementation of iron sucrose is a Iron replacement therapy Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or non-responsive to oral iron therapy.

Iron sucrose provides bioavailable iron to replenish depleted iron stores and restore hemoglobin synthesis in patients with iron deficiency anemia.

Iron sucrose provides bioavailable iron to replenish depleted iron stores and restore hemoglobin synthesis in patients with iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or non-responsive to oral iron therapy.

At a glance

Generic nameSupplementation of iron sucrose
SponsorMedical University of Vienna
Drug classIron replacement therapy
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron sucrose is a stable complex of iron (III) hydroxide with sucrose that delivers iron intravenously for rapid absorption and utilization by erythroid precursor cells. The iron is incorporated into hemoglobin and myoglobin, restoring oxygen-carrying capacity and correcting anemia. This formulation is particularly useful in patients who cannot tolerate oral iron or require rapid iron repletion, such as those with chronic kidney disease or heavy menstrual bleeding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Supplementation of iron sucrose

What is Supplementation of iron sucrose?

Supplementation of iron sucrose is a Iron replacement therapy drug developed by Medical University of Vienna, indicated for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or non-responsive to oral iron therapy.

How does Supplementation of iron sucrose work?

Iron sucrose provides bioavailable iron to replenish depleted iron stores and restore hemoglobin synthesis in patients with iron deficiency anemia.

What is Supplementation of iron sucrose used for?

Supplementation of iron sucrose is indicated for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or non-responsive to oral iron therapy.

Who makes Supplementation of iron sucrose?

Supplementation of iron sucrose is developed and marketed by Medical University of Vienna (see full Medical University of Vienna pipeline at /company/medical-university-of-vienna).

What drug class is Supplementation of iron sucrose in?

Supplementation of iron sucrose belongs to the Iron replacement therapy class. See all Iron replacement therapy drugs at /class/iron-replacement-therapy.

What development phase is Supplementation of iron sucrose in?

Supplementation of iron sucrose is FDA-approved (marketed).

What are the side effects of Supplementation of iron sucrose?

Common side effects of Supplementation of iron sucrose include Hypophosphatemia, Hyperkalemia, Injection site reactions, Headache, Nausea, Hypersensitivity reactions.

Related